Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | GSTO1 | P78417 | 3/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118922 | 0.96 | BDKRB1 (0.55) | BDKRB1GAAALDH1A1L3MBTL1FABP4 | |
| SCHEMBL4032501 | 0.91 | BDKRB1 (0.53) | BDKRB1GAAALDH1A1L3MBTL1FABP4 | |
| SCHEMBL5115197 | 0.83 | MCOLN3 (0.51) | BDKRB1GAAALDH1A1L3MBTL1FABP4 | |
| SCHEMBL5124107 | 0.83 | BDKRB1 (0.42) | BDKRB1ALDH1A1L3MBTL1FABP4WDR5 | |
| SCHEMBL3999966 | 0.81 | GSTO1 (0.51) | BDKRB1ALDH1A1L3MBTL1GSTO1VCAM1 | |
| SCHEMBL5117215 | 0.80 | HTT (0.56) | GAAALDH1A1L3MBTL1FABP4GSTO1 | |
| SCHEMBL4464906 | 0.80 | BDKRB1 (0.56) | BDKRB1ALDH1A1L3MBTL1GSTO1WDR5 | |
| SCHEMBL3992988 | 0.79 | BDKRB1 (0.46) | BDKRB1ALDH1A1L3MBTL1GSTO1VCAM1 | |
| SCHEMBL5111158 | 0.79 | MCOLN3 (0.52) | BDKRB1GAAALDH1A1L3MBTL1FABP4 | |
| SCHEMBL4040827 | 0.77 | BDKRB1 (0.66) | BDKRB1ALDH1A1HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | BDKRB1 1217/4885GAA 215/4885ALDH1A1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.